

























































published: 25 November 2013
doi: 10.3389/fonc.2013.00288
A predictive genetic signature for response to
fluoropyrimidine-based neoadjuvant chemoradiation in
clinical Stage II and III rectal cancer
Jason Chan1, Michael T. Kinsella2, Joseph E.Willis3, Huankai Hu3, Harry Reynolds Jr 4, Conor Delaney 4,
Andrea McCulla5, Steve Deharo5, Miika Ahdesmäki 5,Wendy Louise Allen6, Patrick G. Johnston6 and
Timothy J. Kinsella1*
1 Department of Radiation Oncology, Brown University, Providence, RI, USA
2 Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
3 Department of Pathology, Case Medical Center, Cleveland, OH, USA
4 Department of Surgery, Case Medical Center, Cleveland, OH, USA
5 Almac Diagnostics, Craigavon, UK
6 Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, UK
Edited by:
Kwan-Hwa Chi, Shin-Kong Memorial
Hospital, Taiwan
Reviewed by:
Daniel Grant Petereit, Rapid City
Regional Hospital, USA
Skye Hung-Chun Cheng, Koo
Foundation Sun Yat-Sen Cancer
Center, Taiwan
*Correspondence:
Timothy J. Kinsella, Department of
Radiation Oncology, Rhode Island
Hospital, Physician’s Office Building,
Suite 130, 110 Lockwood Street,
Providence, RI 02903, USA
e-mail: tkinsella@lifespan.org
Purpose: Pre-operative chemoradiation (CRT) is currently the standard of care for patients
with clinical stage II and III rectal cancer but only about 45% of patients achieve tumor
downstaging and <20% of patients achieve a pathologic complete response. Better meth-
ods to stratify patients according to potential neoadjuvant treatment response are needed.
We used microarray analysis to identify a genetic signature that correlates with a patholog-
ical complete response (pCR) to neoadjuvant CRT. We performed a gene network analysis
to identify potential signaling pathways involved in determining response to neoadjuvant
treatment.
Patients and Methods: We identified 31 T3–4 N0–1 rectal cancer patients who were
treated with neoadjuvant fluorouracil-based CRT. Eight patients were identified to have
achieved a pCR to treatment while 23 patients did not. mRNA expression was analyzed
using cDNA microarrays. The correlation between mRNA expression and pCR from pre-
treatment tumor biopsies was determined. Gene network analysis was performed for the
genes represented by the predictive signature.
Results: A genetic signature represented by expression levels of the three genes EHBP1,
STAT1, and GAPDH was found to correlate with a pCR to neoadjuvant treatment. The dif-
ference in expression levels between patients who achieved a pCR and those who did
not was greatest for EHBP1. Gene network analysis showed that the three genes can be
connected by the gene ubiquitin C (UBC).
Conclusion: This study identifies a 3-gene signature expressed in pre-treatment tumor
biopsies that correlates with a pCR to neoadjuvant CRT in patients with clinical stage II and
III rectal cancer. These three genes can be connected by the gene UBC, suggesting that
ubiquitination is a molecular mechanism involved in determining response to treatment.
Validating this genetic signature in a larger number of patients is proposed.
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INTRODUCTION
TREATMENT OF LOCALLY ADVANCED RECTAL CANCER
An estimated 40,340 new cases of rectal cancer will be diagnosed
in 2013 (1). Rectal cancer is a highly treatable and often curable
disease when localized. Surgery is the mainstay of treatment. The
2-year local recurrence rates after surgery alone for Stage II and
III rectal cancers are <10% (2, 3). The 5-year survival rates after
surgery alone for T3 and T4 rectal cancers vary from 44 to 60%
and from 25 to 30% in patients with lymph node involvement (4).
The addition of postoperative radiation improves local-
regional control whilst the use of postoperative chemotherapy
is associated with a survival benefit (5). When combined, the
use of postoperative radiation together with a fluorouracil-
based radiosensitizer significantly improves the results of therapy
for rectal carcinoma with a poor prognosis, as compared with
postoperative radiation alone (6).
The advent of pre-operative chemoradiation (CRT) represents
a new phase in improving rectal cancer treatment allowing for
tumor downstaging prior to radical resection. This has been associ-
ated with considerable advantages over postoperative approaches
(7) including improvement of local disease control (4, 8–14), over-
all and cancer specific-survival (15), and allowing for sparing of
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the rectal sphincter in some patients where an abdomino-perineal
resection would have been necessary (16, 17). Another important
advantage of pre-operative CRT is allowing for pathological assess-
ment of the resected specimen after neoadjuvant treatment, which
has been shown to be predictive of treatment outcomes (18–21).
PREDICTING RESPONSE TO NEOADJUVANT CHEMORADIATION
Despite these advantages, the clinical and pathological response
to pre-operative CRT is extremely variable between individual
patients. Only about 45% of treated patients achieve T stage
downstaging (16, 22–24), and <20% of treated patients achieve
a pathological complete response (pCR), where no viable tumor
cells are found in the resected specimen after neoadjuvant treat-
ment (23, 25, 26). Several predictive clinical factors have been
identified including tumor stage, tumor mobility, proportion of
rectal circumference involved by tumor, and tumor differentiation
(9). Radiation dose and time elapsed from radiation to surgery are
also important (4, 13, 27).
Furthermore, such variable individual responses to neoad-
juvant treatment raise the question of genetic and epigenetic
heterogeneity of rectal tumors and motivate the need to dis-
cover predictive biological markers to stratify patients according
to potential treatment response. This would ultimately have the
benefit of modifying treatment so that, for example, patients with
little likelihood of having a therapeutic benefit from pre-operative
CRT would be spared the potential morbidity (28). Conversely,
patients predicted to have a pCR might be spared the morbidity
associated with surgery (29–31).
A recent review of predictive biomarkers for response to neoad-
juvant CRT identified six biomarkers with more than five studies
in the literature: p53, epidermal growth factor receptor (EGFR),
Ki-67, p21, bcl-2/bax, and thymidylate synthase (TS) (32, 33).
The predictive value of these biomarkers is mostly derived from
immunocytochemistry analyses of pre-operative biopsy mater-
ial. p53 is the most studied biomarker but conflicting data exists
regarding the predictive value of p53 expression and p53 mutations
(8, 9, 34, 35). Among these single gene biomarkers, TS currently
appears to be the most promising avenue of investigation in pre-
dicting response to CRT. TS is the primary target for 5-FU activity
and its increased expression has been identified as a poor prog-
nostic and predictive factor in various cancers (36–41). A recent
prospective study stratified 37 out of 135 rectal cancer patients into
a poor risk group based on genotypes that correlate with increased
TS expression and activity (42). However, the data are not consis-
tent throughout the literature as regards the significance of TS
expression level as a predictor of response to FU-CRT (32). This is
in part due to small study populations and differences in treatment
regimens but much of the discrepancy in the literature probably
derives from the complex nature of these pathways, which single
gene expression assays cannot adequately explain.
One of the most useful recent advances in the ability to inves-
tigate biological systems is the advent of cDNA array technol-
ogy. DNA microarrays contain oligonucleotide or cDNA probes
for measuring the expression of thousands of genes in a sin-
gle hybridization experiment and allow for the potential to
discover predictive genetic “signatures” that are represented by
numerous genes products (43–46). A recent study discovered a
genetic signature of 13 miRNAs that correlated with pCR after
neoadjuvant CRT in locally advanced rectal cancer patients (47).
Using cDNA microarrays in this manner, we attempt to iden-
tify gene clusters associated with pCR after neoadjuvant CRT in a
small group of rectal cancer patients. We obtained formalin-fixed
paraffin-embedded specimens taken from pre-treatment biop-
sies of previously treated patients and identified 8 patients who
achieved pCR and 23 patients who did not achieve pCR. We found
a genetic signature that was found to be correlated with pCR
and was independent of clinical factors. This genetic signature
consisted of three genes EHBP1, STAT1, and GAPDH. Network
analysis revealed that all three genes can be connected through
a single gene Ubiquitin C (UBC), suggesting that ubiquitination
may be a molecular mechanism involved in determining response
to FU-CRT.
MATERIALS AND METHODS
PATIENTS AND TISSUE SPECIMENS
Forty patients treated at the University Hospitals Case Medical
Center with clinical Stage II and III rectal cancer who underwent
pre-treatment biopsies and post-treatment pathological assess-
ment of tumor response to neoadjuvant CRT were included in this
study. The retrospective inclusion criteria were locally advanced
T3/T4 N0–1 M0 rectal cancer by endoscopic ultrasound (EUS)
in patients who were not previously treated. The exclusion cri-
teria included recurrent colorectal cancer or the presence of a
known coagulopathy. Biopsies were taken at the time of initial
diagnosis. Patients then received standard CRT. Finally, patients
underwent total mesorectal excision. Multiple sections of pre-
operative cancer biopsies (average 10 per case) were subjected
to laser capture microdissection using an Arcturus Veritas Laser
Capture Microdissection Microscope (Applied Biosystems).
CHEMORADIATION THERAPY
Patients received 54–63 Gy at 1.8 Gy daily fractions over 6–7 weeks
depending on tumor volume determined by CT and EUS. CT-
based 3-D conformal radiation therapy treatment planning was
used. 5-FU was administered as a continuous infusion throughout
radiation therapy. A dose of 200–250 mg/m2/day was administered
typically through a surgically placed port.
PATHOLOGY
Post-chemoradiation therapy resection specimens were processed.
The resected specimens were fixed in formaldehyde and a mini-
mum of four paraffin blocks were processed for each sample. The
tumor response in the surgical resection specimen was graded
according to previously published criteria (48). Tumor regression
of the primary tumor was measured by laser capture microscopy
to compare the amount of tumor versus stromal tissues. Tumor
regression scores were assigned as follows: grade 0, no residual
tumor; grade 1, rare residual tumor cells; grade 2, fibrosis with
residual cancer; and grade 3, dominant residual cancer. pCR was
defined by a tumor regression score of 0. Non-pCR was defined
by tumor regression scores of 2 and 3. One patient did not receive
neoadjuvant radiation therapy and was excluded from analysis.
Seven specimens were assigned a tumor regression score of 1 and
were excluded from analysis.
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GENETIC ANALYSIS
mRNA extracted from viable tumor cells derived from formalin-
fixed paraffin-embedded tissue were amplified and converted to
cDNA using the NuGEN WT-Ovation FFPE RNA amplificationV2
Table 1 | Patient characteristics.






S0740F0024 F ANED 126 0
S0740F0027 F ANED 38 0
S0740F0028 M ANED 13 0
S0740F0032 M DNED 55 0
S0740F0034 F ANED 56 0
S0740F0040 M AWD 5 0
S0740F0001 M ANED 52 0
S0740F0002 M ANED 27 0
S0740F0017 M AWD 6 2
S0740F0020 M AWD 24 2
S0740F0030 M ANED 15 2
S0740F0036 M AWD 99 2
S0740F0038 F DWD 14 2
S0740F0025 M ANED 48 3
S0740F0026 F ANED 53 3
S0740F0029 M AUNK 14 3
S0740F0031 M AWD 21 3
S0740F0033 F AWD 14 3
S0740F0035 M AUNK 3.5 3
S0740F0037 M ANED 14.5 3
S0740F0039 M AUNK 29 3
S0740F0004 M AUNK 17 3
S0740F0005 M AWD 54 3
S0740F0006 M ANED 48 3
S0740F0007 M ANED 30 3
S0740F0008 M ANED 46 3
S0740F0009 M AWD 27 3
S0740F0010 M ANED 47 3
S0740F0011 F AWD 7 3
S0740F0012 F ANED 48 3
S0740F0016 M ANED 48 3
Patient status: ANED, alive, no evidence of disease; AWD, alive with disease;
DWD, dead with disease; DNED, dead, no evidence of disease; AUNK, alive dis-
ease unknown. Tumor regression score: 0= no residual tumor; 2=fibrosis with
residual cancer; 3=dominant residual cancer, no regression.
kit (NuGEN Technologies, Inc.). The cDNA was fragmented and
labeled using the NuGEN Encore kit and hybridized to the Almac
Diagnostics Colorectal Cancer DSA® arrays. Each microarray con-
tains cDNA probes for measuring the expression of thousands of
genes in a single hybridization experiment. One tumor specimen
was identified as an outlier following data quality and integrity
assessment and was excluded from the analysis.
STATISTICAL METHODS
Following percent present filtering and 50% variance intensity
filtering, signature generation starting from 8496 probe sets was
conducted. Genetic signatures consisted of predictive probe set
signatures of different sizes that were evaluated under cross
validation and utilizing forward feature selection for the selec-
tion of the optimal signature, following the best practices of
the MicroArray Quality Control consortium (49). The perfor-
mance of each genetic signature was evaluated in two ways:
the area under the Receiver Operating Characteristic (ROC)
curve (AUC) for response detection and the signature’s inde-
pendence from clinical covariates. After the highest performing
genetic signature was identified, we performed a permutation
test by randomly shuffling the response information for the
samples. Finally, functional and topological analyses were per-
formed to identify biological entities associated with the gene




Two sample groups were identified from a sub-population of 31
rectal cancer patients with varying response to 5-FU and radiother-
apy (Table 1). Eight responders were defined as having a tumor
regression score of 0 and 23 non-responders defined having a
Table 3 | List of clinical covariates used in testing for independence of
genetic signature prediction.
Clinical covariates
1. Follow up length
2. Date of last follow up
3. Gender
4. Patient status
5. Tumor regression score
6. Response
7. Ethnicity
Table 2 | List of genes that is represented by the genetic signature.
ProbeSet ID Gene symbol Gene title Entrez gene
ADXCRAD_CX760189_at EHBP1 EH domain binding protein 1 23301
ADXCRAG_AL831944_at Antisense Antisense Antisense
AFFX-HUMISGF3A/M97935_MA_at STAT1 signal transducer and activator of transcription 1, 91 kDa 6772
AFFX-HUMGAPDH/M33197_5_at GAPDH Glyceraldehyde-3-phosphate dehydrogenase 2597
The AdXCRAG_AL831944 probe set is an antisense transcript and does not represent gene function. The genetic signature, therefore, represents the three genes:
EHBP1, STAT1, and GAPDH.
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FIGURE 1 | AUC (A) and independence to clinical covariates p-values (B) for the highest performing genetic signature.
FIGURE 2 | Permutation test AUC results over all considered signature lengths. The 4-probe set genetic signature is indicated with the vertical dashed line.
The true AUC curve is just above the 95% but below the 97.5% quantile.
tumor regression score of 2 or 3. At the time of analysis, 16 patients
were alive without evidence of disease, 9 were alive with evidence
of disease, 4 were alive with unknown disease status, 1 died with
evidence of disease, and 1 died with no evidence of disease.
GENETIC SIGNATURE GENERATION
Gene expression signatures were generated in rectal cancer patients
treated with neoadjuvant CRT. A 4-probe set signature was dis-
covered to be the highest performing genetic signature (Table 2).
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FIGURE 3 | Network analysis results. Genes present in the genetic signature are colored gray.
Each probe set consists of genetic probes with a single genetic
target. One probe set targets an antisense transcript and there-
fore does not provide information about gene function. The other
three genes represented by this genetic signature include EHBP1,
STAT1, and GAPDH.
Repeated testing of patient samples showed that the aver-
age area under ROC curves (AUC) was 65%. To test whether
this genetic signature was an independent predictive factor,
we identified a list of clinical factors to rule out intercorrela-
tions (Table 3). The clinical covariate independence p-values
were on average below 0.05 or above 1.3 on the log scale
(Figure 1).
This signature was further studied in a permutation analysis.
A null hypothesis AUC distribution was produced by randomly
shuffling the patient response information. The median, 95, and
97.5% quantiles are shown in Figure 2. The 4-probe set genetic
signature on average generates an AUC above the 95% quantile
but below the 97.5% quantile. Therefore, the selected signature
does not pass permutation testing at the stringent 97.5% quantile
or p-value of 0.05 threshold, but this may, in part, be due to the
small sample size.
FUNCTIONAL ANALYSIS OF THE GENETIC SIGNATURE
Network analysis revealed that all three genes represented by
the genetic signature can be connected through a single gene
UBC (Figure 3). Furthermore, the probe set for EHBP1 was
identified as the strongest differentiator between the responders
and non-responders.
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DISCUSSION
This study identifies a genetic signature that is predictive of
pathologic complete response (pCR) to neoadjuvant CRT and
found to be independent from clinical factors. The genetic sig-
nature was represented by the three genes: EHBP1, STAT1, and
GAPDH. EHBP1 expression level was found to be the greatest
differentiator between patients that achieved pCR and patients
that did not. Functional analysis revealed good connectivity
between the genes as they can all be connected through the
gene UBC.
pCR PREDICTS TREATMENT OUTCOMES
The correlation between this novel genetic signature and pCR is
significant because pCR is a predictor of treatment outcomes.
Local control rates are improved in patients who achieve pCR
(23). Additionally, the 5-year disease-free survival is about 83%
for patients that achieve pCR and about 66% for those that do not
(19, 48). Validating this genetic signature in a larger study pop-
ulation will be needed to assess whether this genetic signature is
predictive of treatment outcomes in addition to pCR.
EHBP1, STAT1, GAPDH, AND UBIQUITINATION
EHBP1 is a gene that is thought to be involved with endocytic
trafficking by mediating actin reorganization (50). An intron
of EHBP1 is known to bear two SNPs that are associated with
prostate cancer (51), but otherwise this gene has not previously
been linked with cancer. Whether these SNPs affect gene expres-
sion or other downstream signaling effects are also currently
unknown.
STAT1 is transcription factor complex that is involved in pro-
apoptotic and anti-proliferative signaling pathways (52), and has
been implicated in numerous cancers including colorectal can-
cer (53). Specific ligand-receptor tyrosine kinase binding induces
tyrosine phosphorylation by JAK1 and JAK2, which recruit STAT1
molecules to form STAT1 dimers. STAT1 dimers translocate to the
nucleus and function as part of a transcription factor complex.
Increased expression of STAT1 has been reported to be a favorable
prognostic factor in colorectal cancer (54, 55).
GAPDH catalyzes the sixth step in glycolysis and has been
implicated in promoting apoptosis (56). GAPDH has been
reported to be overexpressed in colorectal cancer (57), but has
not been studied as a prognostic or predictive factor.
Ubiquitin C is a small regulatory protein that labels proteins
to be transported and destroyed in proteasomes (58), and its role
in colorectal carcinogenesis and colorectal cancer prognosis was
recently reviewed (59). In most sporadic colorectal cancers, muta-
tions in APC prevent the ubiquitination of β-catenin, which is a
transcription factor involved in cell proliferation. The downstream
effects are that β-catenin is not recognized by the proteasome and
excess β-catenin will translocate into the nucleus.
CONCLUSION
This study identifies a 3-gene signature that correlates with a pCR
to neoadjuvant CRT in patients with clinical stage II and III rectal
cancer. These three genes can be connected by the gene UBC, sug-
gesting that ubiquitination is a molecular mechanism involved in
determining response to neoadjuvant CRT.
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